A
Alan L Stewart
Researcher at King's College London
Publications - 17
Citations - 3945
Alan L Stewart is an academic researcher from King's College London. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 14, co-authored 17 publications receiving 3705 citations.
Papers
More filters
Journal ArticleDOI
A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.
R. C. Coombes,Emma Hall,Lorna Gibson,Robert Paridaens,Jacek Jassem,Thierry Delozier,Stephen E. Jones,Isabel Alvarez,Gianfilippo Bertelli,Olaf Ortmann,Alan S. Coates,Emilio Bajetta,D. Dodwell,Robert E. Coleman,Lesley Fallowfield,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,Alan L Stewart,N Stuart,Claire Snowdon,M. Carpentieri,Giorgio Massimini,Judith M Bliss +24 more
TL;DR: Exemestane therapy after two to three years ofTamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxIFen treatment.
Journal ArticleDOI
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes,Lucy Kilburn,Claire Snowdon,Robert Paridaens,Robert E. Coleman,Stephen E. Jones,Jacek Jassem,Cjh van de Velde,Thierry Delozier,Isabel Alvarez,L. Del Mastro,Olaf Ortmann,K Diedrich,Alan S. Coates,Emilio Bajetta,Stig Holmberg,D. Dodwell,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,John F. Forbes,Monica Castiglione,N Stuart,Alan L Stewart,Lesley Fallowfield,Gianfilippo Bertelli,Emma Hall,R. G. Bogle,M. Carpentieri,E Colajori,M Subar,E. Ireland,Judith M Bliss +33 more
TL;DR: The results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen persist after treatment, and translate into a modest improvement in overall survival.
Journal ArticleDOI
Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study
Walter Jonat,Manfred Kaufmann,Willi Sauerbrei,Roger W. Blamey,Jack Cuzick,Moïse Namer,Ignac Fogelman,J.C.J.M. de Haes,A. de Matteis,Alan L Stewart,Wolfgang Eiermann,I. Szakolczai,Mike K. Palmer,Martin Schumacher,M. Geberth,B. Lisboa +15 more
TL;DR: Goserelin offers an effective, well-tolerated alternative to CMF in premenopausal patients with ER-positive and node-positive early breast cancer and side effects related to estrogen suppression were initially higher with goserelin, but when gose Relin treatment stopped, reduced to a level below that observed in the CMF group.
Journal ArticleDOI
First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).
R.K. Agrawal,Abdulla Alhasso,Peter Barrett-Lee,Judith M Bliss,Peter Bliss,D. Bloomfield,Joanna Bowen,A Murray Brunt,Ellen M. Donovan,M. Emson,Andrew Goodman,Adrian Harnett,Joanne S Haviland,Ronald Kaggwa,James P Morden,Anne Robinson,Simmons S,Alan L Stewart,M. Sydenham,Isabel Syndikus,Jean Tremlett,Y. Tsang,Duncan Wheatley,K Venables,John Yarnold +24 more
TL;DR: At 3years median follow-up, 28.5Gy in5 fractions is comparable to 50Gy in 25 fractions, and significantly milder than 30Gy in 5 fractions, in terms of adverse effects in the breast, according to physician-assessed moderate/marked adverse effects.
Journal ArticleDOI
Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer.
TL;DR: The data indicate that CD105 might be a valuable novel angiogenic marker for identifying breast cancer patients who are at high risk of developing metastasis and neither CD105/TGF β1 complex nor TGFβ1 levels correlated with tumour progression.